D&O

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 2, 2024
Skin care, Research, Lung cancer, Ovarian cancer, DP, Head, Conference, Face, Cell, Skin cancer, Immunotherapy, TIL, Clinical, Cancer, Cervical cancer, HNSCC, George Washington University, Patient, Gene, American Academy, D&O, IND, Centricity, AACR, Glioblastoma, Skin, Breast cancer, Scalp, Melanoma, Patent, SITC, Private law, FDA, BRD4, Food, Pharmaceutical industry

MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • The latter clearance was significant since there are no drugs specifically approved to treat early stages I and II of cSCC.
  • As of February, the first two patients in our first cohort have completed treatment with PH-762 with no reported adverse events.
  • In 2023 we implemented a cost rationalization program driven by our transition from discovery research to product development.
  • At December 31, 2023 we had cash of $8.5 million as compared with $11.8 million at December 31, 2022.

Enthusiast Gaming Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Monday, April 1, 2024
Conference call, Conference, Growth, CFO, Enthusiasm, Webcast, Chairperson, EGLX, User (computing), Overalls, Insurance, D&O, Bank statement, Adjustment, TSX, Content, Enthusiast Gaming, Audit committee, Video game

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three (“Q4 2023”) and 12 months ended December 31, 2023 (“FY 2023”).

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three (“Q4 2023”) and 12 months ended December 31, 2023 (“FY 2023”).
  • “We are moving swiftly to simplify and streamline our business in order to improve financial performance,” commented Adrian Montgomery, Board Chair and interim CEO of Enthusiast Gaming.
  • Direct Sales (included in revenue) increased by 3% to $13.2 million in Q4 2023 compared to $12.8 million in Q4 2022.
  • Adjusted EBITDA loss was $3.0 million in Q4 2023 compared to an Adjusted EBITDA loss of $5.2 million in Q4 2022.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, PIN, LTD, Intermountain Health, Radiology, Exercise, Medical imaging, Patient, Health, Fatty liver disease, Action Replay, Policy, Sale, AI, D&O, Google Images, Teleradiology, NANO, GAAP, ARC, Depreciation, Marketing, FDA, Vertebral compression fracture, Hand, Cryptocurrency

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Retrieved on: 
Wednesday, March 27, 2024
Research, Malignancy, Absorption, PD, CSF, Imatinib, Central nervous system, International, Patient, Gastrointestinal tract, Journal, CML, NDA, Pharmacist, Traffic barrier, Cerebrospinal fluid, Insurance, D&O, Dark Ages, Therapy, Division, Blood, Bone marrow, FDA, SAD, Physician, Approximation error, Pharmaceutical industry

The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.

Key Points: 
  • The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.
  • Inhibikase will host a conference call and webcast to discuss its full-year 2023 financial results and business highlights tomorrow, March 28, 2024, at 8:00am ET.
  • The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics.
  • After the live webcast, the event will be archived on Inhibikase’s website for approximately 90 days after the call.

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.

ParaZero Announces 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Environment, Growth, EASA, Nitrox, Partnership, Black Square, Travel, IPO, Insurance, D&O, OEM, European, Safety, KULR, Marketing, TEL

TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.

Key Points: 
  • TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.
  • ParaZero closed its IPO on July 31, 2023, issuing 1,950,000 ordinary shares.
  • ParaZero's CEO, Boaz Shetzer, stated, "2023 was a crucial year for ParaZero, as we continued to push the boundaries of innovation in drone safety.
  • Full Year 2023 Financial Highlights:
    Sales increased by $60,390, or 10.8% to $620,508 for the year ended December 31, 2023, compared to $560,118 for the year ended December 31, 2022.

Health and safety emerges as top risk facing global directors according to WTW’s and Clyde & Co’s latest survey

Retrieved on: 
Wednesday, March 20, 2024
Transfer, Health, Crime, Climate change, Risk management, Alternative risk transfer, Risk, Education, Mental health, Clyde & Co, D&O, WTW, Safety, Occupational safety and health

LONDON, March 20, 2024 (GLOBE NEWSWIRE) -- Health & safety emerges as the top risk for directors and officers according to the 2024 Global Directors’ and Officers’ Survey Report from WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, and Clyde & Co, a leading global law firm.

Key Points: 
  • LONDON, March 20, 2024 (GLOBE NEWSWIRE) -- Health & safety emerges as the top risk for directors and officers according to the 2024 Global Directors’ and Officers’ Survey Report from WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, and Clyde & Co, a leading global law firm.
  • Overall, health and safety was considered the top risk with 84% of global directors, officers and risk managers ranking it as very or extremely important, closely followed by cyber-attack (including cyber extortion) risks on 79%.
  • Jeremy Wall, Head of Global FINEX, WTW, said: “We are pleased to be launching the 2024 Global Directors’ and Officers’ Survey Report in collaboration with Clyde & Co.
  • “While the last five years have seen cyber and data breaches being a top risk for directors and officers, it was a surprise to see Health & Safety be considered the top risk.

Lifeist Announces Results of Annual General and Special Meeting of Shareholders

Retrieved on: 
Wednesday, March 20, 2024
Remuneration, Science, Proxy, Sale, Public sector, Insurance, D&O, Drink, AGSM, Special, Mikra, Management

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced the results of the Company’s Annual General and Special Meeting of the shareholders held on March 14, 2024 (the “AGSM”).

Key Points: 
  • TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced the results of the Company’s Annual General and Special Meeting of the shareholders held on March 14, 2024 (the “AGSM”).
  • Clearhouse LLP, Chartered Public Accountants were appointed as the Company's auditor to hold office until the next annual meeting of shareholders or until its successor is duly appointed, at a remuneration to be fixed by the Board.
  • The special resolution for the proposed sale of the Company’s CannMart Group did not meet a super majority and therefore was not approved.
  • The proposed sale of the CannMart Group was intended to divest Lifeist of the continued negative cash flow that the cannabis business has cost shareholders since inception.

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 14, 2024
MGMT, Research, Survival, ASH, CD33, Environment, Patient, GBM, Neoplasm, Temozolomide, D&O, IND, AACR, Glioblastoma, Exposition, Research and development, Society, CD123, PFS, Cell, DRI, Cranial cavity, Pharmaceutical industry

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
  • “IN8bio entered 2024 with significant momentum behind the company,” said William Ho, CEO and co-founder of IN8bio.
  • “Despite the difficult environment in 2023, the IN8bio team executed operationally and successfully advanced our programs.
  • Cash position: As of December 31, 2023, the Company had cash of $21.3 million, compared to $18.2 million as of December 31, 2022.